Search Results | Cancer Research | American Association for Cancer Research

1-20 of 79

2 3 4

Sort by

Sort Order Select

Journal Articles

The Two-Hit Hypothesis Meets Epigenetics

Jean-Pierre Issa

Cancer Res (2022) 82 (7): 1167–1169.

DOI: https://doi.org/10.1158/0008-5472.CAN-22-0405

Published: 01 April 2022

View article

Journal Articles

Abstract 4331: Potential role of the splicing factor SF3B1 in epigenetic regulation and activation of p53 signaling

Sandra Deliard, Yasuyuki Okamoto, Jozef Madzo, Somnath Pandey, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2019) 79 (13_Supplement): 4331.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4331

Published: 01 July 2019

View article

Journal Articles

Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler

Somnath Pandey, Hanghang Zhang, Carlos A. Barrero, Salim Merali, Xavier Graña, Jean-Pierre Issa

Cancer Res (2018) 78 (13_Supplement): 2995.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2995

Published: 01 July 2018

View article

Journal Articles

Abstract IA15: Multiple targetable pathways for epigenetic therapy

Jean-Pierre Issa

Cancer Res (2017) 77 (22_Supplement): IA15.

DOI: https://doi.org/10.1158/1538-7445.NEWFRONT17-IA15

Published: 14 November 2017

View article

Journal Articles

Abstract LB-100: Potential role of the splicing factor SF3B1 in epigenetic regulation

Sandra Deliard, Yasuyuki Okamoto, Jozef Madzo, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2017) 77 (13_Supplement): LB-100.

DOI: https://doi.org/10.1158/1538-7445.AM2017-LB-100

Published: 01 July 2017

View article

Journal Articles

Abstract 3359: TET1 mediated hypomethylation activates oncogenic signaling pathways in triple negative breast cancer

Charly Ryan Good, Andrew Kelly, Jozef Madzo, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2017) 77 (13_Supplement): 3359.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3359

Published: 01 July 2017

View article

Journal Articles

Abstract 2659: A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer

Charly R. Good, Jozef Madzo, Shinji Maegawa, Nora Engel, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2016) 76 (14_Supplement): 2659.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2659

Published: 15 July 2016

View article

Journal Articles

Abstract 4441: Non-pathogenic bacteria change host DNA methylation in vivo

Ang Sun, Jaroslav Jelinek, Shinji Maegawa, Christian Jobin, Jean-Pierre Issa

Cancer Res (2016) 76 (14_Supplement): 4441.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4441

Published: 15 July 2016

View article

Journal Articles

Abstract 4442: Very low methylation is a novel epigenetic regulatory mechanism in normal tissues and predisposes to hypermethylation in cancer

priyanka madireddi, Jaroslav Jelinek, Justin Lee, Takahiro Sato, Jean-Pierre Issa

Cancer Res (2016) 76 (14_Supplement): 4442.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4442

Published: 15 July 2016

View article

Journal Articles

Abstract 4273: Oncogenic BRAFV600E drives stem cell niche factors-independent growth and tumorigenic transformation in colon organoids

Byunghak Kang, Julie In, Nicholas Zachos, David Huso, Shinji Maegawa, Jean-Pierre Issa, Hariharan Easwaran, Stephen B. Baylin

Cancer Res (2016) 76 (14_Supplement): 4273.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4273

Published: 15 July 2016

View article

Journal Articles

Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy

Takahiro Sato, Matteo Cesaroni, Anthony Tran, Jozef Madzo, Yasuyuki Okamoto, Hanghang Zhang, Shoghag Panjarian, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2016) 76 (2_Supplement): B42.

DOI: https://doi.org/10.1158/1538-7445.CHROMEPI15-B42

Published: 14 January 2016

View article

Journal Articles

Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy

Gail Roboz, Hagop Kantarjian, Patricia Kropf, Ellen Richie, Nitin Jain, Elizabeth Griffiths, Nikola A. Podoltsev, Katherine Walsh, Casey O'Connell, Wendy Stock, David Rizzieri, Raoul Tibes, Todd Rosenblat, Woonbok Chung, Pietro Taverna, Xiang Yao Su, Sue Naim, Mohammad Azab, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): CT321.

DOI: https://doi.org/10.1158/1538-7445.AM2015-CT321

Published: 01 August 2015

View article

Journal Articles

Abstract 1071: Age-dependent DNA methylation in normal breast epithelium and breast cancer

Shoghag B. Panjarian, Carolyn Slater, Jozef Madzo, Jaroslav Jelinek, Xiaowei Chen, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 1071.

DOI: https://doi.org/10.1158/1538-7445.AM2015-1071

Published: 01 August 2015

View article

Journal Articles

Abstract 4612: Genetic variants in epigenetic pathways and risk of multiple cancer types in the GAME-ON consortium

Dominique Scherer, Reka Toth, Linda Kelemen, Angela Risch, Aditi Hazra, Jean Pierre Issa, Victor Moreno, Rosalind A. Eeles, John Quackenbush, Ellen L. Goode, Shuji Ogino, Rayjean Hung, Cornelia M. Ulrich

Cancer Res (2015) 75 (15_Supplement): 4612.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4612

Published: 01 August 2015

View article

Journal Articles

Abstract 2954: Low level methylation (1-20%) or methylation seeds is a distinct epigenetic regulator of gene expression and is a strong predictor of methylation gains in AML and MDS patients

Priyanka Madireddi, Jaroslav Jelinek, Justin Lee, Matteo Cesaroni, Rodrigo Rodrigues, Yan Zhang, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 2954.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2954

Published: 01 August 2015

View article

Journal Articles

Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study

Woonbok Chung, Pietro Taverna, John Lyons, Yong Hao, Mohammad Azab, Hagop Kantarjian, Patricia Kropf, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 2952.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2952

Published: 01 August 2015

View article

Journal Articles

Abstract 2889: Distinct microbiome in colorectal cancers with the CpG Island Methylator Phenotype

Ang Sun, Matteo Cesaroni, Christian Jobin, Carlos Barrero, Jaroslav Jelinek, Jacqueline D. Sautter, Thomas E. Rams, Salim Merali, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 2889.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2889

Published: 01 August 2015

View article

Journal Articles

Abstract 3521: Combined targeting of DNA and histone methylation improves the efficacy and specificity of epigenetic therapy

Takahiro Sato, Matteo Cesaroni, Jaroslav Jelinek, Jean-Pierre Issa

Cancer Res (2015) 75 (15_Supplement): 3521.

DOI: https://doi.org/10.1158/1538-7445.AM2015-3521

Published: 01 August 2015

View article

Journal Articles

Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples

David J. Stewart, Maria I. Nunez, Jaroslav Jelinek, David Hong, Sanjay Gupta, C. Marcelo Aldaz, Jean-Pierre Issa, Razelle Kurzrock, Ignacio I. Wistuba

Cancer Res (2014) 74 (19_Supplement): 2303.

DOI: https://doi.org/10.1158/1538-7445.AM2014-2303

Published: 01 October 2014

View article

Journal Articles

Abstract 5256: Mechanism of field cancerization

Cancer Res (2014) 74 (19_Supplement): 5256.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5256

Published: 01 October 2014

View article

2 3 4

NARROW

The Two-Hit Hypothesis Meets Epigenetics

Abstract 4331: Potential role of the splicing factor SF3B1 in epigenetic regulation and activation of p53 signaling

Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler

Abstract IA15: Multiple targetable pathways for epigenetic therapy

Abstract LB-100: Potential role of the splicing factor SF3B1 in epigenetic regulation

Abstract 3359: TET1 mediated hypomethylation activates oncogenic signaling pathways in triple negative breast cancer

Abstract 2659: A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer

Abstract 4441: Non-pathogenic bacteria change host DNA methylation in vivo

Abstract 4442: Very low methylation is a novel epigenetic regulatory mechanism in normal tissues and predisposes to hypermethylation in cancer

Abstract 4273: Oncogenic BRAFV600E drives stem cell niche factors-independent growth and tumorigenic transformation in colon organoids

Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy

Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy

Abstract 1071: Age-dependent DNA methylation in normal breast epithelium and breast cancer

Abstract 4612: Genetic variants in epigenetic pathways and risk of multiple cancer types in the GAME-ON consortium

Abstract 2954: Low level methylation (1-20%) or methylation seeds is a distinct epigenetic regulator of gene expression and is a strong predictor of methylation gains in AML and MDS patients

Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study

Abstract 2889: Distinct microbiome in colorectal cancers with the CpG Island Methylator Phenotype

Abstract 3521: Combined targeting of DNA and histone methylation improves the efficacy and specificity of epigenetic therapy

Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples

Abstract 5256: Mechanism of field cancerization

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only